Share this content:
Sancuso patch approved for nausea and vomiting
Sancuso patch approved for nausea and vomiting
Antiemesis via transdermal delivery

COMPANY: ProStrakan Inc.

PHARMACOLOGIC CLASS: Antiemetic (5-HT3 receptor blocker)

Granisetron 3.1mg/24hrs; transdermal delivery system (patch).

Prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.

Sancuso uses a transdermal patch system to deliver the antiemetic, granisetron, to the systemic circulation via passive diffusion. The absorption of drug from the patch is variable from patient to patient. A week after applying Sancuso daily in healthy subjects, there was a high intersubject variability in systemic exposure. Maximal concentration was reached at approximately 48 hours after patch application. Granisetron is a selective 5–hydroxytryptamine3 (5-HT3) receptor antagonist with little or no affinity for other serotonin receptors. Receptor sites for 5–hydroxytryptamine3 are located on vagal nerve terminals and in the chemoreceptor trigger zone in the brain. During emetogenic chemotherapy, mucosal enterochromaffin cells release serotonin, which stimulates 5-HT3 receptors, inducing vomiting. By blocking these 5-HT3 receptors, granisetron reduces emesis due to chemotherapy regimens.

A Phase 3 randomized, parallel group, double-blind, doubledummy study involving 641 patients was conducted to evaluate the effectiveness of Sancuso in the prevention of chemotherapy-induced nausea and vomiting. The efficacy of Sancuso was compared to that of oral granisetron 2mg once daily in the prevention of nausea and vomiting in patients receiving multiple- day chemotherapy. The primary endpoint was the proportion of patients with no vomiting and/or retching, no more than mild nausea, and no rescue medication from the first dose until 24 hours after the start of the last day's chemotherapy dose. Sancuso was applied 24-to-48 hours before the first dose of chemotherapy, and was left on for 7 days. Oral granisetron was administered daily 1 hour before each dose of chemotherapy. The patch formulation was effective in 60.2% of patients and the oral administration of granisetron was effective in 64.8% of patients.

≥18yrs: apply 1 patch to clean, dry, intact healthy skin on upper outer arm 24-to-48 hours before chemotherapy; remove at least 24 hours after chemotherapy is completed. May wear patch for up to 7 days. Do not cut patch.

<18yrs: not recommended.

May mask progressive ilieus and/or gastric distention. Avoid direct sun or UV light (cover patch with clothing during use and for 10 days after removing patch). Pregnancy (Cat.B). Nursing mothers.

Do not take with other granisetron products.

Constipation; local irritation (remove patch if severe or if generalized skin reaction occurs), headache.

Report suspected adverse events to Sancuso at (800) Sancuso or FDA at (800) FDA-1088.

Patch—1 For more information call (800) Sancuso or visit  

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs